Malaria drugs and vaccines will help African children live healthier lives. Read about malaria vaccine research in Mali.
Mali is a landlocked west African nation with a highly stratified climate: hot and arid in the north and wet and humid in the south. Malaria is one of the country’s principal causes of death and suffering and is responsible for more than 30 percent of all outpatient hospital visits, according to the World Health Organization. Food- and water-borne diseases, including Hepatitis A, typhoid fever, and schistosomiasis, are also prevalent, particularly near the Niger River.
NIAID has on-site staff in the capital city of Bamako, working in close association with the the faculty of Pharmacy at the University of Sciences, Techniques, and Technology of Bamako (USTTB). NIAID scientists have been active in Mali since the late 1980s; in 2002, the USTTB was selected by NIAID as an International Center of Excellence in Research, with the mission of studying tropical and infectious diseases in endemic areas.
Milestones in NIAID collaborations with the USTTB include the following:
A NIAID clinical trial conducted at the University of Bamako in Mali has shown the dramatic and lasting effect of doxycycline in treating infection with Mansonella perstans, a species of roundworm transmitted to humans by biting midges. This is the first effective treatment found for this neglected tropical disease, which is common in parts of Africa and Central and South America.
Read more about the randomized trial for doxycycline for M. perstans infection.
Malaria Research and Training Center Provides Base for Advanced Research and Training in Mali
NIAID Celebrates 20-Year Partnership with Malian Scientists
back to top
Last Updated December 18, 2013
Last Reviewed October 15, 2012